Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026
Globe Newswire•12/10/2026•07:30 ET
0
Key Highlights
- ➤95% improved on primary endpoint; 86% rated “Much Improved” or “Very Much Improved”
- ➤98% elected to continue QTORIN™ rapamycin after 24-week efficacy period
- ➤QTORIN™ rapamycin systemic exposure at least 40-fold lower than oral sirolimus
- ➤154,986 U.S. patients diagnosed with DSAP during 2018–2025
- ➤QTORIN™ pitavastatin Phase 2 trial anticipated to commence in fourth quarter of 2026
Expert Statements
Wesley H. Kaupinen, Founder and CEO of Palvella Therapeutics
“Palvella Therapeutics”
Phase 3 SELVA Patient, Caregiver, and Clinician Interviews Highlight Meaningful Clinical Improvements and High Treatment Satisfaction With QTORIN™ Rapamycin
SELVA Maximal-Use Pharmacokinetic Substudy Demonstrates Low and Stable Systemic Rapamycin Exposure Over 24 Hours
Get started
Create a free account to read the full story.